Companies in #Blood-Brain Barrier Delivery
Found 1 company operating in this sector.
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease. The company was formed in 1996 to commercialise research from Northwestern University showing that soluble oligomers — rather than insoluble plaque — are the early and persistent trigger of synaptic dysfunction in Alzheimer's. Its lead candidate, sabirnetug (ACU193), is a humanised monoclonal antibody that selectively binds AβOs; a subcutaneous formulation is being developed with Halozyme's ENHANZE technology, and Acumen is collaborating with JCR Pharmaceuticals on an Enhanced Brain Delivery (EBD) programme using transferrin-receptor-targeted blood-brain-barrier transport. In October 2026 the company reported that the Phase 2 ALTITUDE-AD trial of intravenous sabirnetug missed its primary endpoint and discontinued development of the asset, moving to cash-conservation measures and an evaluation of strategic alternatives.